Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Satoru TaguchiTaketo KawaiYoshiki AmbeKenjiro KishitaniKazuma SugimotoJimpei MiyakawaYu NakamuraMichio NodaTomoyuki KanekoJun KameiDaisuke ObinataKenya YamaguchiShigenori KakutaniYoshitsune FuruyaYujiro SatoYukari UemuraYoshiyuki AkiyamaYuta YamadaYusuke SatoDaisuke YamadaYutaka EnomotoHiroaki NishimatsuTetsuya FujimuraHiroshi FukuharaTohru NakagawaSatoru TakahashiHaruki KumePublished in: International journal of urology : official journal of the Japanese Urological Association (2023)
EV and platinum rechallenge showed equivalent oncological outcomes, even after PSM, and both treatments should therefore be effective treatment options for post-platinum, post-pembrolizumab advanced UC.